-
公开(公告)号：US20240166740A1
公开(公告)日：2024-05-23
申请号：US18317241
申请日：2023-05-15
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Erica ULLMAN , Aynur HERMANN , Ella IOFFE , Elena BUROVA , Gavin THURSTON
IPC: C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , C07K16/2818 , A61K2039/505
Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号：US20210355184A1
公开(公告)日：2021-11-18
申请号：US17317475
申请日：2021-05-11
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jie DAI , Maria del Pilar MOLINA-PORTELA , Ella IOFFE , Markus MOHRS
Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.
-
公开(公告)号：US20180186883A1
公开(公告)日：2018-07-05
申请号：US15905653
申请日：2018-02-26
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Nicholas J. PAPADOPOULOS , Andrew J. MURPHY , Gavin THURSTON , Ella IOFFE , Elena BUROVA
CPC classification number: C07K16/2827 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/30 , C07K2317/21 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号：US20180185668A1
公开(公告)日：2018-07-05
申请号：US15905685
申请日：2018-02-26
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Nicholas J. PAPADOPOULOS , Andrew J. MURPHY , Gavin THURSTON , Ella IOFFE , Elena BUROVA
IPC: A61N5/10 , C07K16/28 , A61K45/06 , A61K39/395 , A61K39/00
Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor programmed death-1 (PD-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-1 and a second binding specificity that binds to an autoimmune tissue antigen, another T-cell co-inhibitor, an Fc receptor, or a T-cell receptor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-1 activity, thus providing a means of treating a disease or disorder such as cancer or a chronic viral infection. In other embodiments, the antibodies are useful for enhancing or stimulating PD-1 activity, thus providing a means of treating, for example, an autoimmune disease or disorder.
-
公开(公告)号：US20170101472A1
公开(公告)日：2017-04-13
申请号：US15289032
申请日：2016-10-07
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Erica ULLMAN , Aynur HERMANN , Ella IOFFE , Elena BUROVA , Gavin THURSTON
IPC: C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2818 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
-
Patent Agency Ranking
公开(公告)号：US20250122307A1
公开(公告)日：2025-04-17
申请号：US18669172
申请日：2024-05-20
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Aynur Hermann , Ella IOFFE , Elena BUROVA , Gavin THURSTON , William OLSON
Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号：US20230279070A1
公开(公告)日：2023-09-07
申请号：US18308892
申请日：2023-04-28
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Jie DAI , Maria del Pilar MOLINA-PORTELA , Ella IOFFE , Markus MOHRS
CPC classification number: C07K14/5428 , A61K38/2066 , A61K47/68 , A61K47/6889 , A61P35/00 , C07K1/22 , C07K16/42 , A61K38/00
Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy.
-
公开(公告)号：US20190284277A1
公开(公告)日：2019-09-19
申请号：US16433263
申请日：2019-06-06
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Erica ULLMAN , Aynur HERMANN , Ella IOFFE , Elena BUROVA , Gavin THURSTON
IPC: C07K16/28 , A61K39/395 , A61K45/06
Abstract: The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号：US20210040232A1
公开(公告)日：2021-02-11
申请号：US17070129
申请日：2020-10-14
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Aynur HERMANN , Ella IOFFE , Elena BUROVA , Gavin THURSTON , William OLSON
Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
-
公开(公告)号：US20190048096A1
公开(公告)日：2019-02-14
申请号：US16046551
申请日：2018-07-26
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Aynur HERMANN , Ella IOFFE , Elena BUROVA , Gavin THURSTON , William OLSON
Abstract: The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.024 seconds)
